遅発性ジスキネジア治療薬の世界市場2019-2023

◆英語タイトル:Global Tardive Dyskinesia Treatment Market 2019-2023
◆商品コード:IRTNTR30055
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年10月23日
◆ページ数:113
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

遅発性ジスキネジアとは、統合失調症、双極性障害およびその他の脳状態を含む精神障害の治療に使用する抗精神病薬の副作用として発症する、顔や体の不随意運動を指します。遅発性ジスキネジア治療薬の世界市場は、2019~2023年の間、年平均成長率4.44%で成長すると予測されています。

主な分析対象企業は、F. Hoffmann-La Roche、Merck、Neurocrine Biosciences、Novartis、Teva Pharmaceuticalなどです。

当調査レポートでは、遅発性ジスキネジア治療薬の世界市場について調査・分析し、市場概要、市場環境、遅発性ジスキネジア治療薬市場規模、製品別(AUSTEDO・INGREZZA、その他)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。

・エグゼクティブサマリー
・調査範囲・調査手法
・遅発性ジスキネジア治療薬の世界市場概要
・遅発性ジスキネジア治療薬の世界市場環境
・遅発性ジスキネジア治療薬の世界市場動向
・遅発性ジスキネジア治療薬の世界市場規模
・遅発性ジスキネジア治療薬の世界市場:業界構造分析
・遅発性ジスキネジア治療薬の世界市場:製品別(AUSTEDO・INGREZZA、その他)
・遅発性ジスキネジア治療薬の世界市場:地域別市場規模・分析
・遅発性ジスキネジア治療薬の北米市場規模・予測
・遅発性ジスキネジア治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・遅発性ジスキネジア治療薬のアジア太平洋市場規模・予測
・遅発性ジスキネジア治療薬の主要国分析
・遅発性ジスキネジア治療薬の世界市場:意思決定フレームワーク
・遅発性ジスキネジア治療薬の世界市場:成長要因、課題
・遅発性ジスキネジア治療薬の世界市場:競争環境
・遅発性ジスキネジア治療薬の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About Tardive Dyskinesia
Tardive dyskinesia is the involuntary movement of face and body as a side effect of using antipsychotic drugs for the treatment of mental disorders such as schizophrenia, bipolar disorder, and other brain conditions.
Technavio’s analysts forecast the Global Tardive Dyskinesia Treatment Market to grow at a CAGR of 4.44% during the period 2019-2023.

[Covered in this report]
The report covers the present scenario and the growth prospects of the tardive dyskinesia treatment market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of tardive dyskinesia across the globe.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, tardive dyskinesia treatment market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• F. Hoffmann-La Roche
• Merck
• Neurocrine Biosciences
• Novartis
• Teva Pharmaceutical
Market driver
• Increasing use of antipsychotic drugs across the globe
• For a full, detailed list, view our report

Market challenge
• Lack of awareness
• For a full, detailed list, view our report

Market trend
• Increasing R&D on VMAT2 inhibitors
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2023 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• AUSTEDO and INGREZZA – Market size and forecast 2018-2023
• Others – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• F. Hoffmann-La Roche
• Merck
• Neurocrine Biosciences
• Novartis
• Teva Pharmaceutical
PART 14: APPENDIX
• Research methodology
• List of abbreviations
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Global CNS therapeutics market
Exhibit 02: Segments of global CNS therapeutics market
Exhibit 03: Market segments
Exhibit 04: Market definition – Inclusions and exclusions checklist
Exhibit 05: Market size 2018
Exhibit 06: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 07: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 08: Five forces analysis 2018
Exhibit 09: Five forces analysis 2023
Exhibit 10: Bargaining power of buyers
Exhibit 11: Bargaining power of suppliers
Exhibit 12: Threat of new entrants
Exhibit 13: Threat of substitutes
Exhibit 14: Threat of rivalry
Exhibit 15: Market condition – Five forces 2018
Exhibit 16: Product – Market share 2018-2023 (%)
Exhibit 17: Comparison by product
Exhibit 18: AUSTEDO and INGREZZA – Market size and forecast 2018-2023 ($ millions)
Exhibit 19: AUSTEDO and INGREZZA – Year-over-year growth 2019-2023 (%)
Exhibit 20: Others – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Others – Year-over-year growth 2019-2023 (%)
Exhibit 22: Market opportunity by product
Exhibit 23: Customer landscape
Exhibit 24: Market share by geography 2018-2023 (%)
Exhibit 25: Geographic comparison
Exhibit 26: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 28: Top 3 countries in Americas
Exhibit 29: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 30: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in EMEA
Exhibit 32: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in APAC
Exhibit 35: Key leading countries
Exhibit 36: Market opportunity
Exhibit 37: Molecules in late-stage development
Exhibit 38: Recent approvals by US FDA
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: F. Hoffmann-La Roche – Vendor overview
Exhibit 46: F. Hoffmann-La Roche – Business segments
Exhibit 47: F. Hoffmann-La Roche – Organizational developments
Exhibit 48: F. Hoffmann-La Roche – Segment focus
Exhibit 50: F. Hoffmann-La Roche – Key offerings
Exhibit 51: F. Hoffmann-La Roche – Key customers
Exhibit 52: Merck – Vendor overview
Exhibit 53: Merck – Business segments
Exhibit 54: Merck – Organizational developments
Exhibit 55: Merck – Segment focus
Exhibit 56: Merck – Geographic focus
Exhibit 57: Merck – Key offerings
Exhibit 58: Merck – Key customers
Exhibit 59: Neurocrine Biosciences – Vendor overview
Exhibit 60: Neurocrine Biosciences – Organizational developments
Exhibit 61: Neurocrine Biosciences – Key offerings
Exhibit 62: Neurocrine Biosciences – Key customers
Exhibit 63: Novartis – Vendor overview
Exhibit 64: Novartis – Business segments
Exhibit 65: Novartis – Organizational developments
Exhibit 66: Novartis – Segment focus
Exhibit 67: Novartis – Geographic focus
Exhibit 68: Novartis – Key offerings
Exhibit 69: Novartis – Key customers
Exhibit 70: Teva Pharmaceutical – Vendor overview
Exhibit 71: Teva Pharmaceutical – Business segments
Exhibit 72: Teva Pharmaceutical – Organizational developments
Exhibit 73: Teva Pharmaceutical – Segment focus
Exhibit 75: Teva Pharmaceutical – Key offerings
Exhibit 76: Teva Pharmaceutical – Key customer
Exhibit 77: Validation techniques employed for market sizing
Exhibit 78: List of abbreviations



【掲載企業】

F. Hoffmann-La Roche、Merck、Neurocrine Biosciences、Novartis、Teva Pharmaceutical

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[遅発性ジスキネジア治療薬の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆